Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study.
Ying ChengYong HeWei LiHe-Long ZhangQing ZhouBuhai WangChunling LiuAndrew WaldingMatilde SaggeseXiangning HuangMinhao FanJia WangSuresh S RamalingamPublished in: Targeted oncology (2021)
ClinicalTrials.gov NCT02296125, registered 20 November 2014.